Login / Signup

Dapagliflozin in chronic kidney disease: cost-effectiveness beyond the DAPA-CKD trial.

Phil McEwanJason A DavisPeter D GabbDavid C WheelerEllen BurgessGlenn M ChertowRicardo Correa-RotterKouichi TamuraSalvatore BaroneJuan Jose Garcia Sanchez
Published in: Clinical kidney journal (2024)
Treatment with dapagliflozin may be cost-effective for patients across a wider spectrum of estimated glomerular filtration rates and albuminuria than previously demonstrated, with or without type 2 diabetes, in the UK, Spanish, Italian and Japanese healthcare systems.
Keyphrases